Absci (NASDAQ:ABSI) Releases Quarterly Earnings Results, Hits Estimates

Key Points

• EPS matched estimates at ($0.19) but revenue missed materially ($0.22M vs. $1.39M consensus), the company shows extreme negative margins and had $125.7M in cash and marketable securities with management saying runway into H1 2028.
• ABS-201 remains on track with blinded SAD safety/tolerability/PK data expected next month and proof‑of‑concept readouts in H2 2026 (interim) and early 2027 (full), while Absci added ABS-202 (anti‑prolactin) and is de‑emphasizing oncology to concentrate resources on these franchises.
• The stock traded down about 3.4% to $5.75 on the news, analysts are mixed with a consensus "Hold" and $6.44 target, and insider Andreas Busch bought 100,000 shares at $2.29, increasing his stake.

Absci (NASDAQ:ABSI - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.19) EPS for the quarter, hitting the consensus estimate of ($0.19), FiscalAI reports. Absci had a negative return on equity of 62.33% and a negative net margin of 4,113.68%.The business had revenue of $0.22 million for the quarter, compared to analyst estimates of $1.39 million.

Here are the key takeaways from Absci's conference call:

• ABS-201 is on track—blinded safety/tolerability/PK data from the SAD cohorts is expected next month, with an interim 13‑week proof‑of‑concept readout in H2 2026 and a full 26‑week POC in early 2027, and PK modeling supports roughly 2–3 injections over six months.
• Management projects a >$25 billion U.S. total available market for androgenetic alopecia and cites a target profile (~35 hairs/cm² similar to high‑dose oral minoxidil) that could expand the market, but these figures are forward‑looking and survey‑based.
• The pipeline is expanding within prolactin biology with the addition of ABS-202, an anti‑prolactin receptor antibody aimed at inflammatory/immune indications, signaling strategic focus on a franchise approach beyond AGA and endometriosis.
• Absci is de‑emphasizing oncology and will stop internal funding for ABS‑301 and ABS‑501, narrowing therapeutic diversity and concentrating resources on ABS‑201 and prolactin‑focused programs.
• Financials show $125.7M in cash and marketable securities at March 31, 2026 with management saying runway into H1 2028, Q1 R&D spend rose to $19.3M, and the company is pursuing non‑dilutive partnerships and AI‑driven efficiency gains.

Absci Stock Down 3.4%

NASDAQ ABSI traded down $0.20 during trading on Thursday, hitting $5.75. The stock had a trading volume of 6,413,573 shares, compared to its average volume of 5,095,980. The company has a market capitalization of $893.84 million, a PE ratio of -6.76 and a beta of 2.36. The firm has a 50 day moving average price of $3.29 and a 200 day moving average price of $3.31. Absci has a twelve month low of $2.24 and a twelve month high of $6.24.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ABSI. Needham & Company LLC restated a "buy" rating and issued a $7.00 price objective on shares of Absci in a report on Wednesday, March 25th. Weiss Ratings restated a "sell (d-)" rating on shares of Absci in a report on Monday, April 20th. Finally, Morgan Stanley lowered shares of Absci from an "overweight" rating to an "equal weight" rating and set a $4.32 price objective on the stock. in a report on Thursday, January 8th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $6.44.

Insiders Place Their Bets

In other news, insider Andreas Busch bought 100,000 shares of the company's stock in a transaction on Thursday, March 12th. The stock was bought at an average cost of $2.29 per share, with a total value of $229,000.00. Following the transaction, the insider directly owned 421,446 shares in the company, valued at $965,111.34. The trade was a 31.11% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.49% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Absci

Institutional investors have recently bought and sold shares of the company. Quarry LP acquired a new position in Absci in the 3rd quarter valued at about $26,000. BNP Paribas Financial Markets grew its position in shares of Absci by 91.2% during the second quarter. BNP Paribas Financial Markets now owns 11,287 shares of the company's stock worth $29,000 after buying an additional 5,385 shares in the last quarter. Legal & General Group Plc grew its position in shares of Absci by 45.9% during the second quarter. Legal & General Group Plc now owns 11,690 shares of the company's stock worth $30,000 after buying an additional 3,678 shares in the last quarter. Scientech Research LLC acquired a new position in shares of Absci during the third quarter worth about $31,000. Finally, Russell Investments Group Ltd. grew its position in shares of Absci by 13,965.9% during the third quarter. Russell Investments Group Ltd. now owns 11,534 shares of the company's stock worth $35,000 after buying an additional 11,452 shares in the last quarter. 52.05% of the stock is owned by institutional investors and hedge funds.

Absci Company Profile

Absci Corporation NASDAQ: ABSI is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company's Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci's offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.